StockDriftsStockDriftsTop 14 Johnson & Johnson Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INC | 45.3% | 2.45M | $345.1M | +0.00%(+0) | $31.30(+350.86%) | 2026-09-30 | |
| NBTX | NANOBIOTIX | 23.01% | 5.62M | $175.2M | +0.00%(+0) | $7.83(+341.20%) | 2026-09-30 | |
| MGTX | MEIRAGTX HLDGS PLC | 9.59% | 6.64M | $73.1M | +0.00%(+0) | $10.47(-10.18%) | 2026-09-30 | |
| RAPP | RAPPORT THERAPEUTICS INC | 7.87% | 1.78M | $60.0M | +0.00%(+0) | $23.26(+18.40%) | 2026-09-30 | |
| CTNM | CONTINEUM THERAPEUTICS INC | 3.49% | 1.98M | $26.6M | +0.00%(+0) | $17.61(-48.95%) | 2026-09-30 | |
| XNCR | XENCOR INC | 2.45% | 748.1K | $18.7M | +0.00%(+0) | $36.39(-31.38%) | 2026-09-30 | |
| LEGN | LEGEND BIOTECH CORP | 2.13% | 814.6K | $16.2M | +0.00%(+0) | $45.81(-52.93%) | 2026-09-30 | |
| FATE | FATE THERAPEUTICS INC | 1.05% | 3.38M | $8.0M | +0.00%(+0) | $73.03(-97.17%) | 2026-09-30 | |
| CVRX | CVRX INC | 0.92% | 4.02M | $7.0M | +0.00%(+0) | $22.65(-93.75%) | 2026-09-30 | |
| PRCT | PROCEPT BIOROBOTICS CORP | 0.86% | 357.9K | $6.5M | +0.00%(+0) | $38.15(-48.10%) | 2026-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +35.12% | +146.69% | +1.65% | +8.54% |
| Top 20 Holdings Unweighted | +16.62% | +58.60% | -6.29% | -27.75% |
Johnson & Johnson reports $761.69M in US-listed equity holdings across 15 positions in its most recent 13F filing. Its largest disclosed positions are PTGX (45.3%), NBTX (23.0%) and MGTX (9.6%). The top 20 holdings account for 96.99% of reported assets. Its disclosed equity book has returned +146.69% on a three-year cumulative basis. Figures reflect the Q3 2026 filing.
Sign up free to track Johnson & Johnson, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Johnson & Johnson’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 200406). View Johnson & Johnson’s 13F filings on SEC